Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-12-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（二）
Board/Management Information Classification · 100% confidence The document is a formal statement nominating an individual as an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with legal and regulatory requirements, and independence criteria. There is no financial data, no discussion of financial results, no mention of shareholder voting results, or any other report type. The document is clearly related to board/management information, specifically about board member nomination. The document length is 3378 characters, which is relatively short and consistent with a nomination statement rather than a full report. Therefore, the most appropriate classification is Board/Management Information (MANG).
2019-12-10 Chinese
关于靶向CD19自体嵌合抗原受体T细胞输注剂获得药物临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a clinical trial notification from the National Medical Products Administration (国家药品监督管理局) for a new drug (targeting CD19 CAR-T cell therapy). It is a regulatory announcement about a milestone in drug development, specifically the approval to start clinical trials. The document is short (987 characters), contains no financial data or financial statements, and does not represent a financial report or earnings release. It is not a report publication announcement since it does not mention any report being attached or published. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category related to financial or corporate governance filings.
2019-12-06 Chinese
关于全资子公司获得药品一致性评价注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Bioengineering (Group) Co., Ltd. regarding its wholly-owned subsidiary receiving a drug consistency evaluation registration approval from the National Medical Products Administration. It details the drug name, specifications, approval number, regulatory basis, and risk warnings. The document is short (1243 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category related to compliance and approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-12-02 Chinese
关于签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds related to a non-public stock issuance by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the amount raised, the opening of special accounts for the funds, and the responsibilities of the parties involved in supervising the use of the funds. There is no financial statement or comprehensive financial report included, nor is it a report publication announcement. The content focuses on capital raising and the management of those funds, which fits the category of Capital/Financing Update (CAP). The document length is 2630 characters, which is relatively short but contains substantive information about capital raising and fund supervision, not just a brief notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2019-11-11 Chinese
关于公司董事、高级管理人员减持计划完成及终止减持计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion and termination of a share reduction plan by company directors and senior management. It details the number of shares planned to be reduced, actual shares reduced, dates, and prices. It also confirms compliance with relevant laws and regulations and states that the reduction does not affect control or governance. This is a report of personal share transactions by company directors and executives, fitting the definition of Director's Dealing (DIRS). The document length is 2119 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DIRS.
2019-11-08 Chinese
关于公司董事减持计划完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a company director (范清林). It details the number of shares reduced, the method of reduction, dates, and the shareholding before and after the reduction. It references compliance with relevant securities laws and regulations. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is short and focused solely on this transaction, with no financial statements or other report content.
2019-11-05 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.